The European Society for Medical Oncology (ESMO) Congress 2025 brought leading oncology experts from around the world together to share the latest advances, emerging trends, and innovative approaches shaping cancer care across multiple disease types and clinical settings. The event provided a unique opportunity for knowledge exchange, collaboration, and discussion of evolving best practices in oncology. Fast Five highlights key insights captured live from the Congress, providing concise and practical takeaways for clinicians, researchers, and healthcare professionals.
In this episode, Caroline Michie, Consultant Medical Oncologist, Honorary Clinical Senior Lecturer, and NRS Research Clinician at the Edinburgh Cancer Centre and the University of Edinburgh, UK, discusses key data from ASCENT-3, TROPION2, and PLANeT, and how these important findings translate into real-world clinical practice, guide treatment decisions in complex scenarios, and inform future decision-making and research priorities in breast cancer care.
Key discussion points include:
- Impact of ASCENT-3 on antibody–drug conjugate use in advanced breast cancer
- What the latest TROPION2 data reveals about the expanding clinical role of antibody–drug conjugates
- Key findings from the PLANeT trial investigating low-dose pembrolizumab in patients with triple-negative breast cancer
- How antibody–drug conjugates and oral selective oestrogen receptor degraders may shape future oncology practice
Read the EMJ Oncology Journal for more cutting-edge insights, including an exclusive interview with the Congress President, expert opinion pieces, in-depth analyses, and comprehensive coverage of the latest developments shaping the global oncology landscape.
Disclosure: Caroline has received consulting fees from AstraZeneca and Daiichi Sankyo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, Novartis, AstraZeneca, Gilead, Menarini Stemline, Exact Sciences Lilly, and Roche; support for attending meetings and/or travel from Novartis, Roche, Gilead, and MSD; participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca, Daiichi Sankyo, Gilead, Menarini Stemline, and Lilly.
